Dengue virus isolation relying on antibody-dependent enhancement mechanism using FcγR-expressing BHK cells and a monoclonal antibody with infection-enhancing capacity

Journal of Clinical Virology

Volumn 52, Issue 3, 2011, Pages 225-230

  Moi, Meng Ling ^a   Lim, Chang Kweng ^a   Tajima, Shigeru ^a   Kotaki, Akira ^a   Saijo, Masayuki ^a   Takasaki, Tomohiko ^a   Kurane, Ichiro ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Antibody dependent enhancement; Dengue; Fc R expressing cells; Virus isolation

Indexed keywords

FC RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4G2; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL CELL; ANTIBODY DEPENDENT ENHANCEMENT; ARTICLE; BLOOD SAMPLING; CELL STRAIN BHK; CONTROLLED STUDY; COPY NUMBER VARIATION; DENGUE VIRUS; HUMAN; INSECT CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT; VIRUS CULTURE; VIRUS GENOME; VIRUS ISOLATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; CELL LINE; CRICETINAE; CULICIDAE; DENGUE; DENGUE VIRUS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 80054694889     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.07.009     Document Type: Article

References (21)

1. World Health Organization. Dengue and dengue haemorrhagic fever. Available at: 2009 [accessed on 01.04.2011]. http://www.who.int/mediacentre/factsheets/fs117/en/index.html/.
2. Srikiatkhachorn A., Gibbons R.V., Green S., Libraty D.H., Thomas S.J., Endy T.P., et al. Dengue hemorrhagic fever: the sensitivity and specificity of the world health organization definition for identification of severe cases of dengue in Thailand, 1994-2005. Clin Infect Dis 2010, 50:1135-1143.
3. Alcon S., Talarmin A., Debruyne M., Falconar A., Deubel V., Flamand M. Enzyme-linked immunosorbent assay specific to dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of patients experiencing primary or secondary infections. J Clin Microbiol 2002, 40:376-381.
4. Hunsperger E.A., Yoksan S., Buchy P., Nguyen V.C., Sekaran S.D., Enria D.A., et al. Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Emerg Infect Dis 2009, 15:436-440.
5. Wang S.M., Sekaran S.D. Evaluation of a commercial SD dengue virus NS1 antigen capture enzyme-linked immunosorbent assay kit for early diagnosis of dengue virus infection. J Clin Microbiol 2010, 48:2793-2797.
6. Levi J.E., Tateno A.F., Machado A.F., Ramalho D.C., de Souza V.A., Guilarde A.O., et al. Evaluation of a commercial real-time PCR kit for detection of dengue virus in samples collected during an outbreak in Goiânia, Central Brazil, in 2005. J Clin Microbiol 2007, 45:1893-1897.
7. Kontny U., Kurane I., Ennis F.A. Gamma interferon augments Fc gamma receptor-mediated dengue virus infection of human monocytic cells. J Virol 1988, 62:3928-3933.
8. Littaua R., Kurane I., Ennis F.A. Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol 1990, 144:3183-3186.
9. Gubler D.J., Kuno G., Sather G.E., Velez M., Oliver A. Mosquito cell cultures and specific monoclonal antibodies in surveillance for dengue viruses. Am J Trop Med Hyg 1984, 33:158-165.
10. Morens T.D.M., Halstead S.B., Repik P.M., Putvatana R., Raybourne N. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 1985, 22(2):250-254.
11. Roehrig J. Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses 2007, World Health Organization, Geneva.
12. Moi M.L., Lim C.K., Kotaki A., Takasaki T., Kurane I. Detection of higher levels of dengue viremia using FcγR-expressing BHK-21 cells than FcγR-negative cells in secondary infection but not in primary infection. J Infect Dis 2011, 203(10):1405-1411.
13. Yamada K., Takasaki T., Nawa M., Kurane I. Virus isolation as one of the diagnostic methods for dengue virus infection. J Clin Virol 2002, 24:203-209.
14. Moi M.L., Lim C.K., Kotaki A., Takasaki T., Kurane I. Discrepancy in dengue virus neutralizing antibody titers between plaque reduction neutralizing tests with Fcgamma receptor (FcγR)-negative and FcγR-expressing BHK-21 cells. Clin Vaccine Immunol 2010, 17(3):402-407.
15. Ito M., Takasaki T., Yamada K., Nerome R., Tajima S., Kurane I. Development and evaluation of fluorogenic TaqMan reverse transcriptase PCR assays for detection of dengue virus types 1 to 4. J Clin Microbiol 2004, 42:5935-5937.
16. Kuno G., Gubler D.J., Vélez M., Oliver A. Comparative sensitivity of three mosquito cell lines for isolation of dengue viruses. Bull World Health Organ 1985, 63(2):279-286.
17. Ito M., Yamada K., Takasaki T., Pandey B., Nerome R., Tajima S., et al. Phylogenetic analysis of dengue viruses isolated from imported dengue patients: possible aid for determining the countries where infections occurred. J Trav Med 2007, 14(4):233-244.
18. Moi M.L., Takasaki T., Kotaki A., Tajima S., Lim C.K., Sakamoto M., et al. Importation of dengue virus type 3 to Japan from Tanzania and Côte d'Ivoire. Emerg Infect Dis 2010, 16(11):1770-1772.
19. World Health Organization Dengue: guidelines for diagnosis, treatment, prevention and control 2009, World Health Organization, Geneva, p. 91-93. new edition.
20. Cardosa M.J. Dengue virus isolation by antibody-dependent enhancement infectivity in macrophages. Lancet 1987, 1(8526):193-194.
21. Henchal E.A., Gentry M.K., McCown J.M., Brandt W.E. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg 1982, 31(4):830-836.